IRVINE, Calif., March 5, 2016 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ: ELOS) a leading global aesthetic device company, and Allergan plc, (NYSE: AGN) a leading global pharmaceutical company, today announced a collaboration to offer three of Syneron Candela's body sculpting and skincare platforms to members of Allergan's healthcare provider loyalty program, Allergan Partner Privileges® (APP®).
"This partnership brings together two very strong aesthetics product portfolios to provide physicians and their patients with comprehensive treatment options for some of the most in demand treatments, including body contouring and skin treatment," said Amit Meridor, Chief Executive Officer of Syneron Medical. "We are excited to partner with Allergan to introduce our products to Allergan's community of aesthetic healthcare providers and their patients. In addition, at a strategic level, this partnership will enhance our ability to build stronger relationships with our customers, supported by a full product solution offering."
Effective immediately, all members of APP® will receive discounted pricing on Syneron's UltraShape and VelaShape III platforms for body contouring and the PicoWay platform for skin treatment. The companies also plan to launch an additional consumer program later this year.
"This partnership allows us to offer our Allergan Partner Privileges® members a special offering on Syneron Candela's innovative aesthetic products, specifically, their VelaShape III and UltraShape body sculpting platforms," said Philippe Schaison, EVP and President Allergan Medical. "This collaboration complements our existing portfolio of industry-leading aesthetic products and further demonstrates Allergan's commitment to providing our customers with a robust portfolio of treatments designed to better address their evolving patient needs."
© 2016 Allergan. All rights reserved. All trademarks are the property of their respective owners.
About Syneron Candela
Syneron Candela is a leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, tattoo removal, improving the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under three distinct brands, Syneron, Candela and CoolTouch, and has a wide portfolio of trusted, leading products including UltraShape, VelaShape, GentleLase, VBeam Perfecta, PicoWay, Profound and elos Plus.
Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Candela are located in Israel. Syneron Candela also has R&D and manufacturing operations in the U.S. The company markets, services and supports its products in 86 countries. It has offices in North America, France,Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.
For additional information, please visit http://www.syneron-candela.com.
Syneron, the Syneron logo, UltraShape, eMatrix and elos are trademarks of Syneron Medical Ltd. and may be registered in certain jurisdictions. The elos (Electro-Optical Synergy) technology is a proprietary technology of Syneron Medical Ltd. All other names are the property of their respective owners.
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.
Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.
For more information, visit Allergan's website at www.allergan.com.
SYNERON SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. The statements made by the Company are based upon management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include the risk factors and other cautionary statements described in the Company's filings with the SEC, including those described in the Company's most recent Annual Report on Form 20-F, and in the filings that Syneron Medical makes with the SEC, and other factors beyond the Company's control. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from those expressed or implied by these forward-looking statements. These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.
Allergan Forward-Looking Statement
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 (such periodic public filings having been filed under the "Actavis plc" name). Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
SYNERON MEDICAL CONTACTS:
Hugo Goldman Chief Financial Officer, Syneron Medical Email: email@example.com
Zack Kubow The Ruth Group 646-536-7020 Email: firstname.lastname@example.org
Investors: Lisa DeFrancesco (862) 261-7152
Media: Mark Marmur (862) 261-7558
SOURCE Syneron Medical Ltd.